

## Possible general offer

## Disclosure of dealings in the shares of China Pioneer Pharma Holdings Limited

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

| Party  | Date        | Description | Nature of dealings                  | Purchase / | Total     | Total amount    | Highest (H) | Lowest (L)  |
|--------|-------------|-------------|-------------------------------------|------------|-----------|-----------------|-------------|-------------|
|        |             | of relevant |                                     | Sale       | number of | paid / received | prices paid | prices paid |
|        |             | securities  |                                     |            | shares    |                 | / received  | / received  |
|        |             |             |                                     |            | involved  |                 |             |             |
| UBS AG | 23 May 2017 | Ordinary    | Hedging of Delta 1 products created | Purchase   | 202,000   | \$593,980.0000  | \$2.9900    | \$2.8900    |
|        |             | shares      | as a result of wholly unsolicited   |            |           |                 |             |             |
|        |             |             | client-driven orders                |            |           |                 |             |             |

End

Note:

UBS AG is an exempt principal trader connected with the Offeree company.

Dealings were made for its own account.

UBS AG is ultimately owned by Chase Nominees Ltd, DTC (Cede & Co.), Nortrust Nominees Ltd.